Schizophrenia Market Pipeline Review, H2 2015 - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/63kfhj/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Schizophrenia Overview
  3. Therapeutics Development
  4. Pipeline Products for Schizophrenia - Overview
  5. Pipeline Products for Schizophrenia - Comparative Analysis
  6. Schizophrenia - Therapeutics under Development by Companies
  7. Schizophrenia - Therapeutics under Investigation by Universities/Institutes
  8. Schizophrenia - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Schizophrenia - Products under Development by Companies
  13. Schizophrenia - Products under Investigation by Universities/Institutes
  14. Schizophrenia - Companies Involved in Therapeutics Development (Partial List)
  • Acadia Pharmaceuticals Inc.
  • Aequus Pharmaceuticals Inc.
  • Aestus Therapeutics, Inc.
  • AgeneBio Inc.
  • Alkermes Plc
  • Amgen Inc.
  • Angita B.V.
  • ANP Technologies, Inc.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • BCWorld Pharm Co. Ltd.
  • BioCrea GmbH
  • Boehringer Ingelheim GmbH
  • Braeburn Pharmaceuticals, Inc.
  • Catalyst Biosciences, Inc.
  • Critical Pharmaceuticals Limited
  • Curemark, LLC
  • Delpor, Inc.
  • Dong Wha Pharma Co., Ltd.
  • Echo Pharmaceuticals B.V.
  • Egis Gyogyszergyar Nyrt
  • Eli Lilly and Company
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • FORUM Pharmaceuticals Inc.
  • Galenea Corp.
  • GeNeuro SA
  • Genovate Biotechnology Co., LTD.
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • GP Pharm, S.A.

For more information visit http://www.researchandmarkets.com/research/63kfhj/schizophrenia

Contacts:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System, Mental Disorders

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.